Emcure Pharmaceuticals Reports 24% Increase in Q4 Net Profit
Emcure Pharmaceuticals Q4 results: Net profit rises 24% to ₹243.74 crore
Business Standard
Image: Business Standard
Emcure Pharmaceuticals Ltd announced a 24% increase in consolidated net profit to ₹243.74 crore for Q4 FY26, driven by strong international sales growth. The company also reported a consolidated revenue of ₹2,469.7 crore for the quarter, reflecting robust performance in international markets despite a softer domestic business.
- 01Consolidated net profit rose to ₹243.74 crore in Q4 FY26.
- 02International business sales grew by 25.7% year-on-year.
- 03Domestic sales increased by 5.2% year-on-year.
- 04Total consolidated revenue reached ₹9,203.54 crore for FY26.
- 05Satish Mehta has been re-appointed as Managing Director for another five years.
Advertisement
In-Article Ad
Emcure Pharmaceuticals Ltd, based in India, reported a 24% increase in consolidated net profit, reaching ₹243.74 crore for the fourth quarter ending March 2026. This growth was primarily fueled by a 25.7% rise in international business sales, amounting to ₹1,493 crore. In contrast, domestic sales rose only 5.2%, totaling ₹977 crore, attributed to challenges with the Zuventus portfolio and team reorganization. For the fiscal year 2026, Emcure's consolidated revenue from operations stood at ₹9,203.54 crore, up from ₹7,896 crore in FY25. CEO Satish Mehta highlighted the company's strategic focus on research and development in complex injectables and biosimilars as key to future growth. The board has also recommended a final dividend of ₹3.6 per share, pending shareholder approval.
Advertisement
In-Article Ad
The strong financial performance indicates potential job stability and growth for employees and stakeholders of Emcure Pharmaceuticals.
Advertisement
In-Article Ad
Reader Poll
Do you think Emcure Pharmaceuticals will continue to grow in the next fiscal year?
Connecting to poll...
Read the original article
Visit the source for the complete story.